Targeting A2AR with negative allostericmodulators (NAMs) is a promising approach for cancer immunotherapy:unlike the orthosteric antagonists currently in use, which face competitiveand off-target limitations, NAMs leverage a noncompetitive, saturablemechanism that enhances receptor selectivity. The gene discussed is ADORA2A; the disease is cancer.